Orion Oyj
ORION CORPORATION MANAGERS’ TRANSACTIONS 5 MARCH 2021 at 11.00 EET
Orion Corporation: Managers’ transactions – Jukka Ylppö
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
____________________________________________
Person subject to the notification requirement
Name: Ylppö, Jukka
Position: Closely associated person
(1):Person Discharging Managerial Responsibilities In Issuer
Name: Rautelin, Hilpi
Position: Member of the Board
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 74370029VAHCXDR7B745_20210305101001_2
____________________________________________
Transaction date: 2021-03-04
Venue not applicable
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: GIFT,DONATION OR INHERITANCE (MADE)
Transaction details
(1): Volume: 50,000 Unit price: 0.00000
Aggregated transactions
(1): Volume: 50,000 Volume weighted average price: 0.00000
Orion Corporation
Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sequana Medical NV9.7.2025 18:00:00 CEST | Press release
Press release: Transparency Notification from Shareholders
Siili Solutions Oyj9.7.2025 17:30:00 CEST | Press release
Siili Solutions Plc: Share Repurchase 9.7.2025
TCM Group A/S9.7.2025 17:05:00 CEST | Pressemeddelelse
TCM Group A/S: Storaktionærmeddelelse
TCM Group A/S9.7.2025 17:05:00 CEST | Press release
TCM Group A/S: Major shareholder announcement
Bavarian Nordic A/S9.7.2025 16:46:37 CEST | Pressemeddelelse
Bavarian Nordic modtager ny ordre på koppe-/mpoxvacciner fra europæisk land
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom